medigraphic.com
ISSN 1995-9427 (Print)

2023, Number 1

<< Back Next >>

Invest Medicoquir 2023; 15 (1)

Non-alcoholic fatty liver and carotid median intima thickness in hypertensive patients

Brito PCA, Díaz-Perera Fernández G, Alonso MMI, Galindo EM

Language: Spanish
References: 27
Page:
PDF size: 174.05 Kb.


ABSTRACT

vIntroduction. Cardiovascular diseases are the leading cause of death in patients with non-alcoholic fatty liver disease. Non-alcoholic fatty liver and arterial hypertension are associated with an early increase in carotid intima-media thickness and a higher prevalence of plaques. This increase exists even in the absence of traditional cardiovascular risk factors and metabolic syndrome.
Objective. To describe the characteristics of non-alcoholic fatty liver disease and carotid intima-media thickness in hypertensive patients.
Methods. A cross-sectional descriptive study was carried out at Surgical Medical Research Center from September 2019 to December 2020. The medical records of hypertensive patients were reviewed.
Results. 50 patients were studied. There was a predominance of the male sex. 42% presented hepatic steatosis. Increased carotid median intima thickness was found in both arteries, predominantly on the right (61.9%).
Conclusions. Non-alcoholic fatty liver disease was a frequent finding in patients with arterial hypertension. In hypertensive patients with hepatic steatosis, there was an increase in carotid median intima thickness and the presence of atheromatous plaques.


REFERENCES

  1. Lambis L, Solana JB, Gastelbondo B, Romero D, Garrido D, Puello W, et al. Factores de riesgo asociados a hígadograso de origen no alcohólico en una población del Caribe Colombiano. Rev Col Gastroenterol [Internet]. 2016Abr-Jun [citado 12 Jul 2019];31(2): [aprox. 13p.]. Disponible en:https://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-99572016000200001&lng=en&nrm=iso&tlng=es.

  2. Ampuero J, Romero-Gómez M. Influencia de la enfermedad por hígado graso no alcohólico en la enfermedadcardiovascular. Gastroenterol Hepatol [Internet]. 2012 Oct [citado 11 Jul 2019];35(8): [aprox. 37p.]. Disponibleen: https://www.elsevier.es/es-revista-gastroenterologia-hepatologia-14-articulo-influencia-enfermedad-porhigado-graso-S0210570512000866.

  3. Arab JP, Dirchworlf M, Álvares–da-Silva M, Barrera F, Benítez C, Castellanoa-Fernandez M, et al. Latin AmericanAssociation for the study of the liver (ALEH) practice guidance for thr diagnosis and treatment of non-alcoholicfatty liver disease. Annals of Hepatology [Internet]. 2020 Oct [cited 2021 Mar13];19:674-90. Available from:https://www.sochob.cl/web1/wp-content/uploads/2020/12/Latin-American-Association-for-the-study-of-theliver-ALEH-practice-guidance-for-the-diagnosis-and-treatment-of-non-alcoholic-fatty-liver-disease.pdf

  4. Albhaisi S, Issa D, Alkhouri N. Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden.HepatoBiliary Surg Nutr [Internet]. 2018 Jul [cited 2021 Mar24];7(5):389-91. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230834/pdf/hbsn-07-05-389.pdf.

  5. Mikolasevic I, Milic S, Wensveen TT, Grgic I, Jakopcic I, Stimac D, et al. Nonalcoholic fatty liver disease - Amultisystem disease? World J Gastroenterol [Internet]. 2016 Nov [cited 2021 Mar23];22(43):9488-505. Availablefrom: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116593/pdf/WJG-22-9488.pdf.

  6. Martínez González A, León Álvarez JL, Marcos Gutiérrez Y. Evaluación ultrasonografía de la disfunción endotelialen la hipertensión arterial esencial. Rev Acta Médica [Internet]. 2018 [citado 13 Mar 2021];19(1):1-9. Disponibleen: https://www.researchgate.net/profile/Jorge-Leon-Alvarez/publication/330200712_Evaluacion_ultrasonografica_de_la_disfuncion_endotelial_en_la_hipertension_arterial_esencial_Ultrasonographic_evaluation_of_endothelial_dysfunction_in_essential_hypertension/links/5c33437ba6fdccd6b599a938/Evaluacion-ultrasonografica-de-la-disfuncion-endotelial-en-la-hipertensionarterial-esencial-Ultrasonographic-evaluation-of-endothelial-dysfunction-in-essential-hypertension.pdf.

  7. Fassio E, Dirchwolf M, Barreyro FJ, Adrover R, Alonso MI, Amante M, et al. Guía de diagnóstico y tratamientodel hígado graso no alcohólico. Asociación Argentina para el estudio de las enfermedades del hígado, año2019. Medicina [Internet]. 2020 Mar [citado 2 Mar 2021];80(4):371-87. Disponible en:https://www.medicinabuenosaires.com/revistas/vol80-20/n4/371.pdf.

  8. Rodríguez Granillo GA, Arufe D, Berg G. Grasa epicárdica y esteatosis hepática como marcadores de riesgocardiovascular. Rev Argent Cardiol [Internet]. 2020 [citado 2 May 2021]; 88:343-54. Disponible en:https://www.old2.sac.org.ar/wp-content/uploads/2020/09/v88n4a10.pdf.

  9. Mostaza JM, Pintó X, Armario P, Masana L, Ascaso JF, Valdivielso P, et al. Estándares SEA 2019 para el controlglobal del riesgo cardiovascular. Clin Investig Arterioscler [Internet]. 2019 Abr [citado 12 Abr 2021];31(S1):1-43. Disponible en: https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0214916819300464.pdf?locale=es_ES&searchIndex=.

  10. del Busto Mesa A, Cabrera Rego JO, Guanche Valenciano O. Cintura hipertrigliceridémica y enfermedad porhígado graso no alcohólico en pacientes hipertensos. Rev cubana med [Internet]. 2017 Abr [citado 12 Jul2019];56(1): [aprox. 10p.]. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232017000100002&lng=es.

  11. Rosero Caiza GE. Grados de hipertensión arterial y factores de riesgo cardiovascular asociados en pacienteshipertensos que acuden a la consulta externa del hospital Delfina Torres de Concha de Esmeraldas período deenero a febrero del 2018. [Tesis en Internet]. Quito: Pontificia Universidad Católica del Ecuador; 2018 [citado24 Mar 2021]. 102 p. Disponible en:http://repositorio.puce.edu.ec/bitstream/handle/22000/14983/TESIS%20DE%20GRADOS%20DE%20HTA%20Y%20FRC%20ASOCIADOS%20EN%20PACIENTES%20HIPERTENSOS%20QUE%20ACUDEN%20A%20LA%20CONSULTA%20EXTERNA%20.pdf?sequence=1&isAllowed=y.

  12. Kim KH, Song IG, Kwon TG, Park JB, Kim KS, Kim WS et al. Impact of different antihypertensives on carotidarterial wall thickness. J Clin Hypertens [Internet]. 2018 [cited 2021 Mar 13]; 20:248-54. Available from:https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.13189.

  13. Castellanos Fernández MI, Crespo Ramírez E, del Valle Díaz S, Barreto Suárez E, Díaz Elías JO, Santaló RodríguezL, et al. Non-Alcoholic Fatty Liver Disease in Cuba. MEDICC Rev [Internet]. 2021 Jan [cited 2021 Apr19];23(1):64-71. Available from: https://mediccreview.org/wp-content/uploads/2021/01/MRJan2021-castellanos-Nonalcoholic-Fatty-Liver-Disease-Cuba.pdf

  14. Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Non alcoholic Fatty Liver Disease andthe Heart. J A C C [Internet]. 2019 Mar [cited 2021 Mar24];73(8):948-63. Available from:https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0735109719300166.pdf?locale=es_ES&searchIndex=.

  15. Briseño Bass P, Chávez Pérez R, López Zendejas M. Prevalencia y relación de esteatosis hepática con perfillipídico y hepático en pacientes de chequeo médico. Revista Gastroenterología de México [Internet]. 2019[citado 12 Mar 2021];84(3):290-5. Disponible en:https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0375090618301617.pdf?locale=es_ES&searchIndex=.

  16. Diaz Elías JO, Santaló Rodríguez L, Fernández Sotolongo J, González Hernández O. Evaluación de factores deriesgo en el hígado graso no alcohólico. Arch. Hosp. Univ. "Gen. Calixto García” [Internet]. 2021 Abr [citado 19Abr 2021];9(1): [aprox. 13p.]. Disponible en:http://www.revcalixto.sld.cu/index.php/ahcg/article/view/e633/579.

  17. Rehman Ajmal M, Yaccha M, Azharuddin Malik M, Rabbani MU, Ahmad I, Isalm N, et al. Prevalence ofnonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRPand TNF-a. Indian Heart Journal [Internet]. 2014 Aug [cited 2021 Mar12]; 66:574-9. Available from:https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0019483214002594.pdf?locale=es_ES&searchIndex=.

  18. Miñoso Arabi Y. Hígado graso no alcohólico, grosor íntima medio carotídeo y factores de riesgo aterogénicoen pacientes con aterosclerosis subclinica. tesis maestría. CIRAH;2017. 67p

  19. Díaz Morales MR, Alonso Rodríguez C, Velbes Marquetti P, Hidalgo Costa T. Sobre las asociaciones entre elhígado graso no alcohólico y la insulinorresistencia. Rev Cubana Aliment Nutr [Internet]. 2017 [citado 26 Mar 2021];27(1):81-97. Disponible en: http://www.revalnutricion.sld.cu/index.php/rcan/article/view/253/pdf_21

  20. Ortega Chavarría MJ, Cornelio Rodríguez G, Rodríguez Weber F, Díaz Greene E. Prevalencia del hígado grasono alcohólico y su asociación con las alteraciones bioquímicas en una población mexicana asintomática. ActaMédica Grupo Ángeles [Internet]. 2020 [citado 3 May 2021];18(2):127-32. Disponible en:https://www.medigraphic.com/pdfs/actmed/am-2020/am202b.pdf.

  21. Hong X, Wongtongkam N, Russell Ward P, Xiao S, Wang S, Peng Q, et al. An association of serum ALT withelevated blood pressure in senior adults: a case-control study. CLINICAL AND EXPERIMENTAL HYPERTENSION[Internet]. 2016 Sep [citado 5 May 2021];38(8):691-95. Disponible en:https://www.researchgate.net/profile/Paul-Ward/publication/311561295_An_association_of_serum_ALT_with_elevated_blood_pressure_in_senior_adults_a_case control_study/links/59fa839b458515d20c7d6adb/An-association-of-serum-ALT-with-elevated-bloodpressure-in-senior-adults-a-case-control-study.pdf.

  22. Hong X, Wongtongkam N, Russell Ward P, Xiao S, Wang S, Peng Q, et al. An association of serum ALT withelevated blood pressure in senior adults: a case-control study. CLINICAL AND EXPERIMENTAL HYPERTENSION[Internet]. 2016 Sep [citado 5 May 2021];38(8):691-95. Disponible en:https://www.researchgate.net/profile/Paul-Ward/publication/311561295_An_association_of_serum_ALT_with_elevated_blood_pressure_in_senior_adults_a_case_control_study/links/59fa839b458515d20c7d6adb/An-association-of-serum-ALT-with-elevated-bloodpressure-in-senior-adults-a-case-control-study.pdf.

  23. Jee Fu H, Pei Chien T, Ming Lun Y, Chung Feng H, Ching H, Meng Hsuan H, et al. Risk stratification of nonalcoholicfatty liver disease across body mass index in a community basis. Journal of the Formosan Medical Association [Internet]. 2020 Jan [cited 2021 May22];119(1):89-96. Available from:https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0929664619300051.pdf?locale=es_ES&searchIndex=.

  24. Cortés Rubio JA, Costa Zamora P, Guerra Díaz R, Candela Fernández M, Cortés Costa M. Estudio descriptivo dela esteatosis hepática y la morbilidad asociada en atención primaria. (Estudio ESTEATOAP. Semergen [Internet].2020 Sep [citado 2 Abr 2021];46(6):400-5. Disponible en:https://www.sciencedirect.com/science/article/abs/pii/S1138359320300526.

  25. Sahuquillo Martínez A. Esteatosis hepática no alcohólica en pacientes con síndrome metabólico. [TesisDoctorado en Internet]. Madrid: Universidad Autónoma de Madrid; 2017 [citado 2 Mar 2021]. 140 p.https://repositorio.uam.es/bitstream/handle/10486/681344/sahuquillo_martinez_alicia.pdf?sequence=1.

  26. Pérez Barreda A, Muñoz Álvarez J, Ravelo Llanes K, Abreu Cruz A, Puig Fernández MJ, Aldama Pérez L. Relacióndel grosor íntima media carotídeo con factores de riesgo y lesiones coronarias. Invest Medicoquir [Internet].2015 [citado 5 May 2021];7(1):4-27. Disponible en:http://www.revcimeq.sld.cu/index.php/imq/article/view/298/387.

  27. Jingjing Cai, Xiao-Jing Zhang, Yan-Xiao Ji, Peng Zhang, Zhi-Gang She, Hongliang Li. Nonalcoholic Fatty LiverDisease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Circulation Research [Internet]. 2020 Feb [cited2021 Mar13];126(5):679-704. Available from:https://www.ahajournals.org/doi/epub/10.1161/CIRCRESAHA.119.316337.




2020     |     www.medigraphic.com